XBiotech Inc
NASDAQ:XBIT
XBiotech Inc
NASDAQ:XBIT
Price:
8.74 USD
2.34%
Market Closed
Updated:
May 22, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of XBIT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XBIT
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
XBIT Competitors Multiples
XBiotech Inc Competitors
XBiotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
XBiotech Inc
NASDAQ:XBIT
|
266m USD | 0 | -10.8 | -1.8 | -1.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.7B USD | 5.3 | 48.4 | 13.5 | 20.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.6B USD | 5.7 | 44.8 | 18.8 | 31 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.7B USD | 11.2 | 28.3 | 23.7 | 24.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 8.4 | 28.4 | 23 | 25.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.8B USD | 3.1 | 173.2 | 8.8 | 11.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54.4B USD | 10.6 | -9.1 | -10.2 | -9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33B USD | 3.4 | 28.3 | 14.4 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.6T KRW | 17.7 | 72 | 44.1 | 60.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
